IκB-pp40 Activators
IκB-pp40 Activators are a diverse array of chemical compounds that, through various mechanisms, can indirectly enhance the functional degradation of IκB-pp40, leading to the activation of the NF-κB pathway. Anisomycin, for instance, activates JNK signaling which is known to phosphorylate transcription factors that promote IκB-pp40 degradation, thus intensifying NF-κB activity. BAY 11-7082 and TPCA-1 are IκB kinase inhibitors that can paradoxically trigger compensatory pathways resulting in the activation of NF-κB by affecting IκB-pp40 turnover. Similarly, the proteasome inhibitor MG-132 allows for the accumulation of IκB-pp40, which could lead to an enhanced degradation response upon proteasome reactivation. Compounds like Sulforaphane and PDTC modulate the cellular redox state, impacting NF-κB signaling and thus indirectly influencing IκB-pp40 activity. Parthenolide and Andrographolide, which inhibit NF-κB activation, could lead to increased expression of IκB-pp40 as part of a feedback mechanism to maintain signaling homeostasis.
The modulation of NF-κB pathway components appears to be a common theme among IκB-pp40 Activators. SN50 prevents the nuclear translocation of NF-κB, which may result in a greater cytoplasmic retention of IκB-pp40 and amplify its degradation upon activation. CAPE, as an NF-κB inhibitor, might transiently increase IκB-pp40 levels, which upon subsequent degradation, would enhance NF-κB signaling. Helenalin and Emodin, both act as inhibitors of NF-κB, and through the inhibition, they are hypothesized to upregulate IκB-pp40, preparing it for more rapid degradation upon pathway reactivation. These chemicals, by influencing different aspects of the NF-κB/IκB-pp40 regulatory axis, each contribute to the fine-tuning of IκB-pp40 activity and thus the regulation of NF-κB dependent signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
This antibiotic acts as a JNK activator through the disruption of protein synthesis. JNK activation leads to the phosphorylation of specific transcription factors, which can enhance the degradation of IκB-pp40, resulting in the activation of NF-κB. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
This compound is an IκB kinase inhibitor that prevents IκB phosphorylation, leading to stabilization and subsequent reduction of NF-κB activity. However, this can paradoxically lead to the activation of alternative compensatory pathways that indirectly enhance IκB-pp40 degradation to maintain NF-κB signaling. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can lead to the accumulation of IκB-pp40 due to blocked degradation. The accumulated IκB-pp40 may then be more readily phosphorylated and degraded upon proteasome reactivation, amplifying NF-κB signaling transiently. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
This compound activates Nrf2, which can induce the expression of antioxidant response element (ARE)-driven genes. One of these genes could encode a protein that modulates IκB-pp40 activity indirectly by altering the cellular redox state, which impacts NF-κB signaling. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $33.00 $64.00 | 11 | |
As a metal chelator and NF-κB inhibitor, PDTC can indirectly affect IκB-pp40 by modulating the redox-sensitive components of the NF-κB pathway, leading to altered signaling dynamics. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
This sesquiterpene lactone inhibits NF-κB activation through the inhibition of IκB kinase, which can result in increased IκB-pp40 expression as a feedback response to maintain homeostatic NF-κB signaling levels. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $40.00 | 7 | |
Known to inhibit NF-κB activation, this diterpenoid compound may lead to an upregulation of IκB-pp40 as part of a compensatory mechanism to balance NF-κB signaling. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
An inhibitor of IκB kinase-β (IKK-β), TPCA-1 stabilizes IκB-pp40 by preventing its phosphorylation and subsequent degradation, which may enhance the sensitivity of the NF-κB pathway to activation signals. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $105.00 $214.00 $6255.00 | 2 | |
A naturally occurring anthraquinone that acts as an inhibitor of IκB kinase, potentially leading to increased levels of IκB-pp40 and enhanced degradation upon reactivation of the NF-κB pathway. | ||||||